Industry News (Human Papillomavirus)

Contract Received To Manufacture Vaccines Against HPV

Published in Vaccine Weekly, October 25th, 1999

Novavax, Inc., Columbia, Maryland, announced that the National Cancer Institute (NCI) has awarded a contract to Novavax's Biomedical Services Division (NBSD) in Rockville, Maryland, to manufacture recombinant chimeric virus-like particle vaccines against human papillomavirus (HPV).

These novel recombinant chimeric virus-like particles (VLP) are non-infectious vaccine candidates designed to either treat or prevent HPV infections that cause genital warts and cervical cancer. These HPV vaccines were developed by research and development teams lead by Robin Robinson, PhD, NBSD, and Douglas Lowy, MD of the Laboratory of Cellular Oncology at the National Cancer Institute in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-10-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry